Final-Program-ATS-2023-AP.vp

SUNDAY • MAY 21

43

Target Audience Clinicians (physicians, nurses, fellows, residents, pharmacists), researchers, administrators, regulators and policymakers,or anyone involved in delivery of care and the science of patients with asthma Objectives At the conclusion of this session, the participant will be able to: • understand the evidence behind various options for asthma reliever inhalers, and their strengths and potential limitations. The audience will be able to fill their knowledge gaps about reliever inhalers for both pediatric and adult patients • learn about the practical application of each reliever option for different populations and settings (pediatrics, adults, US, international) and gain knowledge on how to integrate the decision on the choice of reliever in asthma patient management • improve the understanding of challenges and remaining implementation and research gaps in reliever therapy in asthma. The audience will be able to identify implementation gaps in care and begin to develop methods to address those gaps Evidence regarding use of a reliever coupled with inhaled corticosteroids (ICS) in asthma has been mounting and there have been substantial changes in guideline-based recommendations in recent years. Currently, three reliever options are available; short-acting beta-agonist (SABA), ICS plus SABA, and ICS plus formoterol. This symposium will review the current evidence, research gaps, controversies, implementation challenges and equity around the clinical application of each reliever option in asthma in a broad range of patients and settings (mild-severe, pediatric-adults, international-US). The session will enhance understanding of how to choose and use asthma relievers in clinical practice, and identify future research needs. Chairing: F. Holguin, MD, MPH, Aurora, CO K. Sumino, MD, MPH, Saint Louis, MO 9:00 Introduction, Current Options for Asthma Reliever and the Guidelines K. Sumino, MD, MPH, Saint Louis, MO 9:07 Use of ICS Plus SABA As-Needed in Asthma J.C. Cardet, MD, MPH, Tampa, FL 9:22 Use of ICS Plus Formoterol As-Needed in Asthma H. Reddel, MBBS, PhD, Glebe, Australia 9:39 Pediatric Perspective of Reliever Therapy in Asthma F.D. Martinez, MD, Tucson, AZ 9:55 Challenges and Equity in US and Global Perspective Surrounding Choice of Relievers in Asthma F. Holguin, MD, MPH, Aurora, CO 10:11 Panel Discussion/Questions: Panel 1 A. Papi, MD, Ferrara, Italy 10:15 Panel Discussion/Questions: Panel 2 E. Israel, MD, Boston, MA

10:19 Panel Discussion/Questions: Panel 3 H. Reddel, MBBS, PhD, Glebe, Australia 10:23 Panel Discussion/Questions: Panel 4 F.D. Martinez, MD, Tucson, AZ 10:27 Panel Discussion/Questions: Panel 5 F. Holguin, MD, MPH, Aurora, CO 10:29 Panel Discussion/Questions: Panel 6(Moderator) K. Sumino, MD, MPH, Saint Louis, MO

CLINICAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

A11 CARING FOR HISTORICALLY MARGINALIZED PATIENTS: ETHICAL, LEGAL AND ADVOCACY PRIMER FOR PROVIDERS Assemblies on Critical Care; Nursing; Ethics and Conflict of

Interest Committee 9:00 AM - 10:30 AM

Marriott Marquis Washington Marquis Ballroom Salon 5 (Level M2)

Target Audience ICU clinicians including physicians, nurses, and respiratory therapists, as well as healthcare administrators, health policy makers and patient advocates Objectives At the conclusion of this session, the participant will be able to: • understand complexity around care and decision making for patients who are undocumented or crossing state lines to seek medical therapies not offered in their home state • recognize and mitigate issues surrounding care of incarcerated patients and clinician interactions with law enforcement • define new strategies to understand ethical issues surrounding patients medical decision making for patients limited health literacy or with non-traditional alternate decision making structure, or no legally authorized representative In this symposium, we consider practical ethics involved in the care for a wide range of patients with vulnerabilities, due to lack of representation, that may be underappreciated by their providers: internally displaced people and refugees seeking asylum; individuals along the spectrum of criminalization from arrest to incarceration; patients without consistent housing; and those without legally-recognized heteronormative relationships. Additionally, we acknowledge, across all topics, of the effects of systemic racism that disproportionately disenfranchise communities of color. This session presents ethical challenges while also proposing a framework for advocacy for these patient groups from the bedside to the seats of government.

ATS 2023 • Washington, DC